Sinomab Bio B
Sinomab Bio B, also known as Sinomab Bioscience, is a prominent biopharmaceutical company headquartered in Hong Kong. Founded in 2016, the company has rapidly established itself in the biotechnology sector, focusing on the development of innovative therapies for autoimmune diseases and cancer. With a strong operational presence in Asia and expanding into global markets, Sinomab Bio B is recognised for its unique monoclonal antibody products, which leverage advanced technologies to enhance efficacy and safety. The company has achieved significant milestones, including successful clinical trials that underscore its commitment to addressing unmet medical needs. Sinomab Bio B's strategic position in the biopharmaceutical landscape is marked by its dedication to research and development, making it a key player in the industry.
DitchCarbon Score
How does Sinomab Bio B's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sinomab Bio B's score of 33 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Sinomab Bio B's reported carbon emissions
In 2023, Sinomab Bio B reported total carbon emissions of approximately 2,723,220 kg CO2e. This figure includes 31,960 kg CO2e from Scope 1 emissions, which encompass direct emissions from owned or controlled sources, and 2,615,440 kg CO2e from Scope 2 emissions, related to indirect emissions from the generation of purchased electricity and steam. Additionally, the company recorded 75,820 kg CO2e in Scope 3 emissions, which cover other indirect emissions, including business travel and waste generated in operations. In 2022, the total emissions were about 4,618,000 kg CO2e, with Scope 1 emissions at 204,000 kg CO2e and Scope 2 emissions at 8,144,000 kg CO2e. The Scope 3 emissions for that year were approximately 8,348,000 kg CO2e. This indicates a significant reduction in total emissions from 2022 to 2023. Despite these figures, Sinomab Bio B has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of documented climate pledges or science-based targets suggests that while the company is actively reporting emissions, it may not yet have formalised commitments to further reduce its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 6,802.8 | 000,000 | 000,000 | 00,000 |
| Scope 2 | 1,672,797.6 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | 0,000,000 | 0,000,000 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sinomab Bio B is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
